Joshua Jackson

Dr. Joshua Jackson

University of Miami
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2016 in Nature Communications
Verified
Journal Article
Open access
PDF file
MDMichael Daniels
Michael Daniels
JRJack Rivers-Auty
Jack Rivers-Auty
TSTom Schilling
Tom Schilling
NSNicholas G. Spencer
Nicholas G. Spencer
WWWilliam Watremez
William Watremez
DBDavid Brough
David Brough
Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit cyclooxygenase-1 (COX-1) and COX-2 enzymes. The NLRP3 inflammasome is a multi-protein complex responsible for the processing of the proinflammatory cytokine interleukin-1β and is implicated in many inflammatory diseases. Here we show that several clinically approved and widely used NSAIDs of the fenamate class are effective and selective inhibitors of the NLRP3 inflammasome via inhibition of the volume-regulated anion channel in macrophages, independently of COX enzymes. Flufenamic acid and mefenamic acid are efficacious in NLRP3-dependent rodent models of inflammation in air pouch and peritoneum. We also show therapeutic effects of fenamates using a model of amyloid beta induced memory loss and a transgenic mouse model of Alzheimer’s disease. These data suggest that fenamate NSAIDs could be repurposed as NLRP3 inflammasome inhibitors and Alzheimer’s disease therapeutics.

19 October 2017 in Alzheimer's & Dementia
Verified
Journal Article
Open access
KSKatherine J. Sellers
Katherine J. Sellers
CEChristina Elliott
Christina Elliott
JJJoshua Jackson
Joshua Jackson
AGAnshua Ghosh
Anshua Ghosh
ERElena Ribe
Elena Ribe
RKRichard Killick
Richard Killick
Introduction: Synapse loss is the structural correlate of the cognitive decline indicative of dementia. In the brains of Alzheimer's disease sufferers, amyloid β (Aβ) peptides aggregate to form senile plaques but as soluble peptides are toxic to synapses. We previously demonstrated that Aβ induces Dickkopf‐1 (Dkk1), which in turn activates the Wnt–planar cell polarity (Wnt‐PCP) pathway to drive tau pathology and neuronal death.Methods: We compared the effects of Aβ and of Dkk1 on synapse morphology and memory impairment while inhibiting or silencing key elements of the Wnt‐PCP pathway.Results: We demonstrate that Aβ synaptotoxicity is also Dkk1 and Wnt‐PCP dependent, mediated by the arm of Wnt‐PCP regulating actin cytoskeletal dynamics via Daam1, RhoA and ROCK, and can be blocked by the drug fasudil.Discussion: Our data add to the importance of aberrant Wnt signaling in Alzheimer's disease neuropathology and indicate that fasudil could be repurposed as a treatment for the disease.

Verified
Journal Article
Open access
PDF file
CSChen Shen
Chen Shen
ANAnmada Nayak
Anmada Nayak
RMRicardo A. Melendez
Ricardo A. Melendez
DWDaniel T. Wynn
Daniel T. Wynn
JJJoshua Jackson
Joshua Jackson
DRDavid J. Robbins
David J. Robbins
Wnt signaling regulates numerous cellular processes during embryonic development and adult tissue homeostasis. Underscoring this physiological importance, deregulation of the Wnt signaling pathway is associated with many disease states, including cancer. Here, we review pivotal regulatory events in the Wnt signaling pathway that drive cancer growth. We then discuss the roles of the established negative Wnt regulator, casein kinase 1α (CK1α), in Wnt signaling. Although the study of CK1α has been ongoing for several decades, the bulk of such research has focused on how it phosphorylates and regulates its various substrates. We focus here on what is known about the mechanisms controlling CK1α, including its putative regulatory proteins and alternative splicing variants. Finally, we describe the discovery and validation of a family of pharmacological CK1α activators capable of inhibiting Wnt pathway activity. One of the important advantages of CK1α activators, relative to other classes of Wnt inhibitors, is their reduced on-target toxicity, overcoming one of the major impediments to developing a clinically relevant Wnt inhibitor. Therefore, we also discuss mechanisms that regulate CK1α steady-state homeostasis, which may contribute to the deregulation of Wnt pathway activity in cancer and underlie the enhanced therapeutic index of CK1α activators.

31 December 2015 in Neural Plasticity
Verified
Journal Article
Open access
PDF file
JPJoshua J. W. Paulin
Joshua J. W. Paulin
PHPeter Haslehurst
Peter Haslehurst
AFAlexander D. Fellows
Alexander D. Fellows
WLWenfei Liu
Wenfei Liu
JJJoshua Jackson
Joshua Jackson
FEFrances Edwards
Frances Edwards
The laying down of memory requires strong stimulation resulting in specific changes in synaptic strength and corresponding changes in size of dendritic spines. Strong stimuli can also be pathological, causing a homeostatic response, depressing and shrinking the synapse to prevent damage from too much Ca2+ influx. But do all types of dendritic spines serve both of these apparently opposite functions? Using confocal microscopy in organotypic slices from mice expressing green fluorescent protein in hippocampal neurones, the size of individual spines along sections of dendrite has been tracked in response to application of tetraethylammonium. This strong stimulus would be expected to cause both a protective homeostatic response and long-term potentiation. We report separation of these functions, with spines of different sizes reacting differently to the same strong stimulus. The immediate shrinkage of large spines suggests a homeostatic protective response during the period of potential danger. In CA1, long-lasting growth of small spines subsequently occurs consolidating long-term potentiation but only after the large spines return to their original size. In contrast, small spines do not change in dentate gyrus where potentiation does not occur. The separation in time of these changes allows clear functional differentiation of spines of different sizes.

6 February 2018 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
WWWilliam Watremez
William Watremez
JJJoshua Jackson
Joshua Jackson
BABushra Almari
Bushra Almari
SMSamantha L. McLean
Samantha L. McLean
BGBen Grayson
Ben Grayson
MHMichael Harte
Michael Harte
Background: With current treatments for Alzheimer’s disease (AD) only providing temporary symptomatic benefits, disease modifying drugs are urgently required. This approach relies on improved understanding of the early pathophysiology of AD. A new hypothesis has emerged, in which early memory loss is considered a synapse failure caused by soluble amyloid-β oligomers (Aβo). These small soluble Aβo, which precede the formation of larger fibrillar assemblies, may be the main cause of early AD pathologies. Objective: The aim of the current study was to investigate the effect of acute administration of stabilized low-n amyloid-β 1-42 oligomers (Aβo 1-42 ) on cognitive, inflammatory, synaptic, and neuronal markers in the rat. Methods: Female and male Lister Hooded rats received acute intracerebroventricular (ICV) administration of either vehicle or 5 nmol of Aβo 1-42 (10 μL). Cognition was assessed in the novel object recognition (NOR) paradigm at different time points. Levels of inflammatory (IL-1β, IL-6, TNF-α), synaptic (PSD-95, SNAP-25), and neuronal (n-acetylaspartate, parvalbumin-positive cells) markers were investigated in different brain regions (prefrontal and frontal cortex, striatum, dorsal and ventral hippocampus). Results: Acute ICV administration of Aβo 1-42 induced robust and enduring NOR deficits. These deficits were reversed by acute administration of donepezil and rolipram but not risperidone. Postmortem analysis revealed an increase in inflammatory markers, a decrease in synaptic markers and parvalbumin containing interneurons in the frontal cortex, with no evidence of widespread neuronal loss. Conclusion: Taken together the results suggest that acute administration of soluble low-n Aβo may be a useful model to study the early mechanisms involved in AD and provide us with a platform for testing novel therapeutic approaches that target the early underlying synaptic pathology.

31 May 2019 in Clinical Psychopharmacology and Neuroscience
Verified
Journal Article
Open access
PDF file
GRGavin Reynolds
Gavin Reynolds
CDCaroline F. Dalton
Caroline F. Dalton
WWWilliam Watrimez
William Watrimez
JJJoshua Jackson
Joshua Jackson
MHMichael Harte
Michael Harte
Gavin P. Reynolds, Caroline F. Dalton, William Watrimez, Joshua Jackson, Michael K. Harte. Clin Psychopharmacol Neurosci 2019;17:314-7. https://doi.org/10.9758/cpn.2019.17.2.314